Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Retained Earnings: 2010-2025

Historic Retained Earnings for Anika Therapeutics (ANIK) over the last 15 years, with Sep 2025 value amounting to $60.5 million.

  • Anika Therapeutics' Retained Earnings fell 35.32% to $60.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $60.5 million, marking a year-over-year decrease of 35.32%. This contributed to the annual value of $71.7 million for FY2024, which is 44.03% down from last year.
  • Anika Therapeutics' Retained Earnings amounted to $60.5 million in Q3 2025, which was down 3.71% from $62.8 million recorded in Q2 2025.
  • Over the past 5 years, Anika Therapeutics' Retained Earnings peaked at $231.4 million during Q3 2021, and registered a low of $60.5 million during Q3 2025.
  • In the last 3 years, Anika Therapeutics' Retained Earnings had a median value of $123.5 million in 2024 and averaged $119.9 million.
  • In the last 5 years, Anika Therapeutics' Retained Earnings grew by 1.87% in 2021 and then slumped by 51.04% in 2024.
  • Over the past 5 years, Anika Therapeutics' Retained Earnings (Quarterly) stood at $225.6 million in 2021, then dropped by 6.59% to $210.7 million in 2022, then crashed by 39.23% to $128.1 million in 2023, then crashed by 44.03% to $71.7 million in 2024, then crashed by 35.32% to $60.5 million in 2025.
  • Its last three reported values are $60.5 million in Q3 2025, $62.8 million for Q2 2025, and $66.8 million during Q1 2025.